Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Scholar Rock, Inc. Logo

Scholar Rock, Inc.

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Link to homepage Investors & Media Press Releases

Investors and Media

Press Releases

Main content section

January 23, 2018

Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation – a Key Physiological Process in Muscle Health

Read More

January 3, 2018

Scholar Rock Announces $47 Million Series C Financing to Advance Innovative Pipeline for SMA, Immuno-Oncology, Fibrosis, and Iron-Restricted Anemias

Read More

September 14, 2017

Scholar Rock Announces Issuance of Broad Patent Covering Therapeutic Approach for Neuromuscular Diseases

Read More

September 14, 2017

Scholar Rock Appoints Heather Faulds as Vice President of Regulatory Affairs

Read More

July 10, 2017

Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium

Read More

July 6, 2017

Scholar Rock Appoints David L. Hallal as Chairman of Board of Directors

Read More

June 28, 2017

Scholar Rock to Develop SRK-015 to Improve Muscle Function in Patients with Spinal Muscular Atrophy

Read More

May 23, 2017

Scholar Rock Announces Drug Development Leaders, Michael Gilman and Shelia Violette, to Join Scientific Advisory Board

Read More

  • First page «
  • Previous page ‹
  • …
  • Page 32
  • Page 33
  • Current page 34
Archived Press Releases

Primary Sidebar

Investor Menu

  • Investors & Media
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR or Media

In this section

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

© 2026 All Rights Reserved
  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use
Scholar Rock, Inc. Logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
  • Our Science
    • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Immuno-Oncology
      • Cancer (solid tumors)
      • Fibrotic Diseases
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us